

FORM 7

LEVITEE LABS INC.

MONTHLY PROGRESS REPORT

Name of CSE Issuer: Levitee Labs Inc. (the "Issuer").

Trading Symbol: LVT

Number of Outstanding Listed Securities: 84,810,444

Date: April 7, 2022

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

February 1

Levitee Labs Inc. has appointed Philip van den Berg as interim chief executive officer and to the board of directors, replacing Pouya Farmand, who will be moving to the position of founder. In his role as founder, Mr. Farmand will continue to work with the company on key business development initiatives and help transition the leadership while Mr. van den Berg will be responsible for day-to-day operations. Mr. Farmand will also be stepping down from the board of directors.

Mr. van den Berg has been appointed as interim chief executive officer of Levitee, effectively immediately. He will also be joining the company's board. Mr. van den Berg is the co-founder and current chief financial officer of Halo Labs Inc. and co-founder of Olympus Capital, one of the first long-short hedge funds in Europe. During his career, Mr. van den Berg has held various positions within research departments, both as an investment analyst and head of research, including Goldman Sachs in London, where he was a founding member of the European research department and acted as a member of the investment committee.

The company also announces that it has closed the first tranche of its previously announced non-brokered private placement offering of 7.5 million units at a price of 20 cents per unit for gross proceeds of \$1.5-million. Each warrant will be exercisable at 40 cents per share for a period of 24 months from the date of issuance. The proceeds raised from this offering will be used by the company for general working capital purposes, marketing and investor relations activity.

2. Provide a general overview and discussion of the activities of management.

See Item 1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies,

provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Item 1.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers or committee members.

See #1

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not applicable.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 7, 2022.

Kelly Abbott

Name of Director or Senior Officer

/s/Kelly Abbott

Signature

COO

Official Capacity

Issuer Details <i>Name of Issuer</i> Levitee Labs Inc.	<i>For Month End</i> February 2022	<i>Date of Report</i> <i>YY/MM/DD</i> 22/04/07
<i>Issuer Address</i> #215 - 800 W. Pender Street		
<i>City/Province/Postal Code</i> Vancouver, BC V6C 1J8	<i>Issuer Fax No.</i>	<i>Issuer Telephone No.</i> (250) 465-8640
<i>Contact Name</i> Philip van den Berg	<i>Contact Position</i> Director	<i>Contact Telephone No.</i> (250) 465-8640
<i>Contact Email Address</i> hello@leviteelabs.com	<i>Web Site Address</i>	